Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1167-1172

  Blombery, Piers ^a   Prince, H Miles ^a,b   Worth, Leon J ^a   Main, Jo ^a   Yang, Melissa ^a   Wood, Erica M ^a   Westerman, David A ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Autologous stem cell transplantation; Infection; Intravenous immunoglobulin; Myeloma

Indexed keywords

IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOODSTREAM INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG USE; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INFECTIOUS COMPLICATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; URINARY TRACT INFECTION; AGAMMAGLOBULINEMIA; AUSTRALIA; AUTOTRANSPLANTATION; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; SURVIVAL; UNIVERSITY HOSPITAL;

ADULT; AGAMMAGLOBULINEMIA; AGED; AUSTRALIA; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 80055083076     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1275-3     Document Type: Article

References (10)

1. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG (1994) Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 343(8905):1059-1063 (Pubitemid 24128204)
2. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A (2003) Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant 31(3):163-170. doi:10.1038/sj.bmt.1703818 (Pubitemid 36305569)
3. Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J, Salmon SE, Barlogie B (1999) High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 17 (7):2173-2179 (Pubitemid 29318850)
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730-751. doi:10.1086/339215 (Pubitemid 34194843)
5. Carlisle PS, Gucalp R, Wiernik PH (1993) Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol 14 (6):320-324
6. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O (2009) Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 27(5):770-781. doi:10.1200/JCO.2008.16.8450
7. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP (1993) High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 118(12):937-942 (Pubitemid 23164130)
8. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH (2000) Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82(7):1261-1265. doi:10.1054/bjoc.1999.1088 (Pubitemid 30145342)
9. Koleba T, Ensom MH (2006) Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 26 (6):813-827. doi:10.1592/phco.26.6.813 (Pubitemid 43807633)
10. Rand KH, Gibbs K, Derendorf H, Graham-Pole J (1991) Pharmacokinetics of intravenous immunoglobulin (Gammagard) in bone marrow transplant patients. J Clin Pharmacol 31 (12):1151-1154